minnesota living: Live & Latest News Updates : Vimarsana.com

Intracoronary Gene Therapy Fast Tracked for Congestive Heart Failure

AB-1002 is an investigational one-time gene therapy that promotes increased production of protein inhibitor 1.

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11.

No Improved Outcomes for HF Patients With Sleep Apnea Using ASV Breathing Devices

While apnea symptoms resolved, no improvement was seen in clinical outcomes

AB-1002 Demonstrates Improvements for Congestive Heart Failure in First-in-Human Study

Improvements were seen in left ventricular ejection fraction, NYHA Functional Class, and Minnesota Living with Heart Failure Questionnaire at 1-year post-dose.

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia (BCDA) Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today...

AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions

BioCardia Reports Third Quarter 2023 Business Highlights

SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...